March 17, 2020 / 10:57 AM / in 18 days

BRIEF-Merck - Top-Line Results From Phase 3 Trials Evaluating Gefapixant, A Treatment For Refractory Or Unexplained Chronic Cough

March 17 (Reuters) - Merck & Co Inc:

* MERCK ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 TRIALS EVALUATING GEFAPIXANT, AN INVESTIGATIONAL TREATMENT FOR REFRACTORY OR UNEXPLAINED CHRONIC COUGH

* MERCK & CO INC - GEFAPIXANT 15 MG TWICE DAILY TREATMENT ARMS DID NOT MEET PRIMARY EFFICACY ENDPOINT IN EITHER PHASE 3 STUDY

* MERCK & CO - GEFAPIXANT DEMONSTRATED STATISTICALLY SIGNIFICANT DECREASE IN 24-HR COUGHS PER HOUR VERSUS PLACEBO AT WEEK 12 AND 24 IN PHASE 3 TRIALS

* MERCK & CO INC - SAFETY AND TOLERABILITY PROFILE OF GEFAPIXANT DURING TRIALS TO DATE IS CONSISTENT WITH PREVIOUSLY REPORTED PHASE 2 STUDY

* MERCK & CO INC - TRIALS WILL CONTINUE FOR LONG-TERM FOLLOW-UP TO COLLECT ADDITIONAL SAFETY DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below